A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
Science · 24.07.2025 · 389 (6758)
DOI: 10.1126/science.ads0239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 24.07.2025. Verfasst von Caroline Weller und 39 weiteren Autor:innen. Beteiligte Einrichtung: Revolution Medicines, Inc., Redwood City, CA, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Aspartic Acid, Cyclophilin A, Neoplasms. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Mutant RAS proteins are among the most prevalent drivers of human cancer, and the glycine to aspartic acid mutation at codon 12 (G12D) is the most common variant. Mutation-selective covalent inhibitors spare RAS in healthy tissue and enable extended pharmacodynamic effect, but covalent targeting of RAS G12D is hindered by low nucleophilicity and high proteomic abundance of carboxylic acids. We overcame these challenges with compounds that bind cyclophilin A (CYPA) to create a neomorphic protein-protein interface between CYPA and active RAS that enables selective, enzyme-like rate enhancement of the covalent reaction between D12 and electrophilic warheads with exceptionally low intrinsic reactivity. This approach yielded orally bioavailable compounds with marked antitumor activity in multiple preclinical models of KRAS G12D cancers, including the investigational agent zoldonrasib (RMC-9805) currently undergoing clinical evaluation (NCT06040541).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Revolution Medicines, Inc., Redwood City, CA, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
- Broad Institute of Harvard and MIT, Cambridge, MA, USA.
ORCID-Profile: Caroline Weller, G Leslie Burnett, Lingyan Jiang, Sujata Chakraborty, Dongyu Zhang, Nicole A Vita, Julien Dilly, Eejung Kim, Kyle Seamon, Diane F Eilerts, Anthony Milin, Abby Marquez, Ciara Helland, Andrea Gould, Tamar Bar Ziv, Phuong Dinh, Shelby L Steele, Zhican Wang, Seema Chugh, Hanrong Feng, Conner Hennessey, Jennifer Roth, Matthew Rees, Melissa Ronan, Brian M Wolpin, William C Hahn, Matthew Holderfield, Elena S Koltun, Mallika Singh, Adrian L Gill, Jacqueline A M Smith, Andrew J Aguirre, Jingjing Jiang, John E Knox, David Wildes
Förderung
- NCI NIH HHS
Zitieren
APA
Weller, C., Burnett, G. L., Jiang, L., Chakraborty, S., Zhang, D., Vita, N. A., Dilly, J., Kim, E., Maldonato, B., Seamon, K., Eilerts, D. F., Milin, A., Marquez, A., Spradlin, J., Helland, C., Gould, A., Ziv, T. B., Dinh, P., Steele, S. L., …, & Wildes, D. (2025). A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors. Science, 389(6758). https://doi.org/10.1126/science.ads0239
Vancouver
Weller C, Burnett GL, Jiang L, Chakraborty S, Zhang D, Vita NA, et al. A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors. Science. 2025;389(6758). doi:10.1126/science.ads0239
BibTeX
@article{Weller2025,
author = {Weller, Caroline and Burnett, G Leslie and Jiang, Lingyan and Chakraborty, Sujata and Zhang, Dongyu and Vita, Nicole A and Dilly, Julien and Kim, Eejung and Maldonato, Benjamin and Seamon, Kyle and Eilerts, Diane F and Milin, Anthony and Marquez, Abby and Spradlin, Jessica and Helland, Ciara and Gould, Andrea and Ziv, Tamar Bar and Dinh, Phuong and Steele, Shelby L and Wang, Zhican and Mu, Yunming and Chugh, Seema and Feng, Hanrong and Hennessey, Conner and Wang, Junning and Roth, Jennifer and Rees, Matthew and Ronan, Melissa and Wolpin, Brian M and Hahn, William C and Holderfield, Matthew and Wang, Zhengping and Koltun, Elena S and Singh, Mallika and Gill, Adrian L and Smith, Jacqueline A M and Aguirre, Andrew J and Jiang, Jingjing and Knox, John E and Wildes, David},
title = {A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors},
journal = {Science},
year = {2025},
volume = {389},
number = {6758},
doi = {10.1126/science.ads0239}
}
EUVIMED